Overview

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Status:
Completed
Trial end date:
2012-04-18
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and efficacy of oral PF-00299804 in patients who have not yet undergone any other drug treatment for recurrent and/ or metastatic head and neck squamous cell cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer